GLP-1 Receptor Agonist Research Protocol
Research protocol for GLP-1 receptor agonist peptides including Semaglutide, Tirzepatide, and Retatrutide, covering dose titration schedules, reconstitution specifics, and monitoring considerations from published clinical research.
Materials Needed
- GLP-1 RA peptide (Semaglutide, Tirzepatide, or Retatrutide) — lyophilized
- Bacteriostatic water
- Insulin syringes (U-100)
- Alcohol swabs
- Research log
- Body composition tracking tools (scale, tape measure)
Dosing Calculator
Calculate the injection volume needed for your target dose.
Result:
Injection Volume
0.100 mL
Syringe Units (U-100)
10.0 units
Doses Per Vial
20
Concentration: 2500 mcg/mL (2.50 mg/mL)
Understand Dose Titration Rationale
GLP-1 receptor agonists require gradual dose escalation to minimize gastrointestinal side effects (nausea, reduced appetite). Published clinical trials for all three compounds (STEP trials for Semaglutide, SURPASS/SURMOUNT for Tirzepatide, Phase 2 for Retatrutide) employed dose titration schedules. Starting at the target dose without titration significantly increases the incidence and severity of GI effects.
Skipping the titration phase is the most common cause of severe nausea in GLP-1 RA research
Tips
- • Dose titration is a core design feature of every major GLP-1 RA clinical trial
- • Review the compound-specific monograph for clinical trial dose details
Reconstitute the Peptide
Follow the standard Reconstitution Protocol. GLP-1 RA peptides are reconstituted identically to other lyophilized peptides. Calculate your reconstitution volume so that your starting dose and maintenance dose are both convenient to measure with an insulin syringe.
Tips
- • For Semaglutide (5 mg vial), reconstituting with 2.5 mL gives 2 mg/mL — convenient for 0.25 mg starting dose (0.125 mL = 12.5 units)
- • Plan your reconstitution concentration around your dose schedule
Semaglutide Titration Schedule (from STEP Trials)
Published Semaglutide titration from the STEP clinical trials: Week 1-4: 0.25 mg once weekly. Week 5-8: 0.5 mg once weekly. Week 9-12: 1.0 mg once weekly. Week 13-16: 1.7 mg once weekly. Week 17+: 2.4 mg once weekly (maintenance). Each dose level is maintained for 4 weeks before escalation.
Tips
- • If GI effects are significant at any dose level, remain at that dose for an additional 2-4 weeks before escalating
- • The 4-week intervals allow GLP-1 receptor adaptation at each dose level
Tirzepatide Titration Schedule (from SURPASS Trials)
Published Tirzepatide titration from SURPASS/SURMOUNT trials: Week 1-4: 2.5 mg once weekly. Week 5-8: 5.0 mg once weekly. Week 9-12: 7.5 mg once weekly (for 10 mg target) or continue at 5.0 mg. Week 13-16: 10.0 mg once weekly. Week 17+: up to 15 mg weekly for highest dose arm. Tirzepatide is a dual GIP/GLP-1 receptor agonist, which may provide improved GI tolerability.
Tips
- • Tirzepatide's dual receptor mechanism (GIP + GLP-1) distinguishes it from pure GLP-1 agonists
- • The starting dose is higher than Semaglutide due to the dual agonist design
Administration Protocol
All GLP-1 RA peptides are administered once weekly via subcutaneous injection, on the same day each week. Follow the Subcutaneous Injection Technique Protocol. Administer at any time of day, with or without food. Rotate injection sites (abdomen, thigh, upper arm) weekly.
If a dose is missed, administer it within 48 hours. If more than 48 hours have passed, skip to the next scheduled dose
Tips
- • Choose a consistent day of the week that is easy to remember
- • There is no requirement for fasting before or after GLP-1 RA administration
Monitoring and Documentation
Track the following throughout the research period: weekly body weight (same time, same conditions), waist circumference (monthly), appetite changes (subjective rating scale 1-10), GI effects (nausea severity/duration), energy levels, and any other observations. Comprehensive documentation enables meaningful analysis of research outcomes.
Tips
- • Weigh at the same time each day (e.g., morning, after waking, before eating)
- • Monthly photographs under consistent conditions provide visual documentation
Duration and Discontinuation
Major clinical trials ran 52-72 weeks. Research suggests that metabolic benefits accumulate over time and may partially reverse upon discontinuation. If discontinuing, some protocols taper the dose back down rather than stopping abruptly, though this specific approach has not been formally studied in clinical trials.
Tips
- • The longest published Semaglutide data extends to 2+ years of continuous use
- • Metabolic parameters (weight, HbA1c) tend to return toward baseline within 6-12 months of discontinuation in clinical trial extension studies
Related Monographs
Semaglutide
An in-depth review of Semaglutide, a long-acting GLP-1 receptor agonist, covering its mechanism of action, albumin-binding pharmacokinetics, and research applications in metabolic health, weight management, and cardiovascular outcomes.
Read monographTirzepatide
An in-depth review of Tirzepatide, the first dual GIP/GLP-1 receptor agonist ('twincretin'), examining its mechanism of action, superior glycemic and weight loss efficacy, and research applications in metabolic health.
Read monographRetatrutide
An in-depth review of Retatrutide, the first triple GLP-1/GIP/glucagon receptor agonist, examining its mechanism of action, glucagon-mediated thermogenesis, and unprecedented weight loss results from Phase 2 clinical trials.
Read monographRelated Protocols
Oral Peptide Administration Protocol
Protocol for administering peptides via the oral route, covering compounds with established oral bioavailability (BPC-157, 5-Amino-1MQ, semaglutide), capsule handling, and timing considerations for gastrointestinal peptide delivery.
Peptide Cycle Planning Protocol
Comprehensive guide to planning peptide research cycles, including on/off scheduling, washout periods, receptor desensitization considerations, and multi-compound sequencing strategies based on published pharmacological principles.
Peptide Degradation Assessment Protocol
Systematic protocol for assessing peptide integrity and detecting degradation in reconstituted solutions, covering visual inspection, pH testing, and functional indicators that signal compromised peptide quality.
Peptide Dosing Calculation Protocol
How to calculate precise research doses from reconstituted peptide solutions, including unit conversions, syringe measurement techniques, and common dose calculations for popular research peptides.